# MiniMed Group, Inc.: overview

MMED · Nasdaq · CIK 2062583 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mmed.md) · [Financials](/companies/mmed/financials.md) · [Filings](/companies/mmed/filings.md) · [Insiders](/companies/mmed/insiders.md)

Latest reported revenue: [$843.0m](/filings/0001628280-26-060926.md) for Q1 FY2027, three months to 2026-07-31, from the 10-Q filed Sep 8, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-060926).

## Last eight quarters

| Line item | Unit | period not labelled (2024-10-25) | period not labelled (2025-01-24) | period not labelled (2025-04-25) | period not labelled (2025-07-25) | period not labelled (2025-10-24) | Q3 FY2026 (2026-01-23) | Q4 FY2026 (2026-04-24) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | [687](/filings/0001628280-26-025777.md) | [724 d](/filings/0001628280-26-045915.md) | [723](/filings/0001628280-26-060926.md) | not reported | [790](/filings/0001628280-26-025777.md) | [837 d](/filings/0001628280-26-045915.md) | [843](/filings/0001628280-26-060926.md) |
| Gross margin | % | not reported | [57.5%](/filings/0001628280-26-025777.md) | [55.9% d](/filings/0001628280-26-045915.md) | [56.6%](/filings/0001628280-26-060926.md) | not reported | [45.8%](/filings/0001628280-26-025777.md) | [57.3% d](/filings/0001628280-26-045915.md) | [55.2%](/filings/0001628280-26-060926.md) |
| Operating margin | % | not reported | [3.1%](/filings/0001628280-26-025777.md) | [(20.4%) d](/filings/0001628280-26-045915.md) | [(1.8%)](/filings/0001628280-26-060926.md) | not reported | [(12.7%)](/filings/0001628280-26-025777.md) | [(11.1%) d](/filings/0001628280-26-045915.md) | [0.6%](/filings/0001628280-26-060926.md) |
| Net margin | % | not reported | [(1.5%)](/filings/0001628280-26-025777.md) | [(23.8%) d](/filings/0001628280-26-045915.md) | [(2.6%)](/filings/0001628280-26-060926.md) | not reported | [(15.1%)](/filings/0001628280-26-025777.md) | [(22.1%) d](/filings/0001628280-26-045915.md) | [0.0%](/filings/0001628280-26-060926.md) |
| Diluted EPS | $ per share | not reported | [(0.04)](/filings/0001628280-26-025777.md) | not reported | [(0.08)](/filings/0001628280-26-060926.md) | not reported | [(0.47)](/filings/0001628280-26-025777.md) | not reported | [0.00](/filings/0001628280-26-060926.md) |
| Free cash flow | $m | not reported | not reported | [26.0 d](/filings/0001628280-26-045915.md) | [(194)](/filings/0001628280-26-060926.md) | not reported | not reported | [(226) d](/filings/0001628280-26-045915.md) | [(90.0)](/filings/0001628280-26-060926.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure.

## Last five fiscal years

| Line item | Unit | FY (2024-04-26) | FY (2025-04-25) | FY2026 (2026-04-24) |
| --- | --- | ---: | ---: | ---: |
| Revenue | $m | [2,469](/filings/0001628280-26-045915.md) | [2,715](/filings/0001628280-26-045915.md) | [3,102](/filings/0001628280-26-045915.md) |
| Gross margin | % | [58.2%](/filings/0001628280-26-045915.md) | [56.3%](/filings/0001628280-26-045915.md) | [54.2%](/filings/0001628280-26-045915.md) |
| Operating margin | % | [(2.8%)](/filings/0001628280-26-045915.md) | [(5.4%)](/filings/0001628280-26-045915.md) | [(6.1%)](/filings/0001628280-26-045915.md) |
| Net margin | % | [(4.5%)](/filings/0001628280-26-045915.md) | [(7.8%)](/filings/0001628280-26-045915.md) | [(10.7%)](/filings/0001628280-26-045915.md) |
| Diluted EPS | $ per share | [(0.44)](/filings/0001628280-26-045915.md) | [(0.84)](/filings/0001628280-26-045915.md) | [(1.30)](/filings/0001628280-26-045915.md) |
| Free cash flow | $m | [(107)](/filings/0001628280-26-045915.md) | [(53.0)](/filings/0001628280-26-045915.md) | [(420)](/filings/0001628280-26-045915.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mmed/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [MASSACHUSETTS FINANCIAL SERVICES CO /MA/](/funds/912938.md) | 2026-06-30 | $124.6m | 8,334,738 |  | Added +1,456,278 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $45.8m | 3,060,615 |  | Added +467,181 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $42.8m | 2,865,703 |  | Added +14,164 |
| [Longaeva Partners L.P.](/funds/2054122.md) | 2026-06-30 | $42.1m | 2,812,970 |  | Reduced −365,684 |
| [Sessa Capital IM, L.P.](/funds/1595849.md) | 2026-06-30 | $29.9m | 2,000,000 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $29.8m | 1,996,489 |  | Added +1,970,314 |
| [NORGES BANK](/funds/1374170.md) | 2026-06-30 | $29.3m | 1,961,002 |  | New +1,961,002 |
| [Rock Springs Capital Management LP](/funds/1595725.md) | 2026-06-30 | $22.7m | 1,520,000 |  | Added +465,000 |
| [ExodusPoint Capital Management, LP](/funds/1736225.md) | 2026-06-30 | $21.5m | 1,437,067 |  | Added +1,027,819 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $16.2m | 1,080,689 |  | Reduced −284,311 |

## Recent filings

[All 108 filings](/companies/mmed/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-16 | 08:30 ET | [8-K](/filings/0001104659-26-116441.md) | 5.01 Change in control; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-116441 |
| 2026-10-13 | 06:00 ET | [8-K](/filings/0001104659-26-115141.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-115141 |
| 2026-09-08 | 16:28 ET | [10-Q](/filings/0001628280-26-060926.md) | Quarterly report, period 2026-07-31 | 0001628280-26-060926 |
| 2026-09-01 | 06:50 ET | [8-K](/filings/0001628280-26-059699.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-059699 |
| 2026-08-21 | 16:15 ET | [DEF 14A](/filings/0001140361-26-034021.md) | Proxy statement, period 2026-10-09 | 0001140361-26-034021 |
| 2026-08-05 | 16:15 ET | [8-K](/filings/0001104659-26-091115.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-091115 |
| 2026-06-29 | 12:09 ET | [10-K](/filings/0001628280-26-045915.md) | Annual report, period 2026-04-24 | 0001628280-26-045915 |
| 2026-06-29 | 09:22 ET | [8-K](/filings/0001104659-26-078588.md) | 5.02 Departure or appointment of officers or directors; 5.08 Item not in the standard list; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-078588 |
| 2026-06-03 | 06:50 ET | [8-K](/filings/0001628280-26-040036.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-040036 |
| 2026-05-18 | 17:09 ET | [8-K](/filings/0001104659-26-063267.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-063267 |

## Latest annual report

[Form 10-K for the fiscal year ended Apr 24, 2026](/filings/0001628280-26-045915.md), filed Jun 29, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 2062583
- Tickers: MMED, MMEDV
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Non-accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 17:19 ET. No prices; not investment advice.